GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Product-specific reference

EXBLIFEP - cefepime and enmetazobactam injection

Read renal action and limits
Local official-label summarySource retrieved 2026-09-10See the evidence for this drug3 sources available - open source summaries, references and comparisons

EXBLIFEP / cefepime enmetazobactam

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (2)
Review first - source-specific qualification

EXBLIFEP: source applicability and renal evidence limits

The table names MDRD but prints mL/min without an indexing explanation. Preserve that wording and resolve method/units with the product label and local pharmacy; do not automatically convert the threshold. Archived-label currency remains a hold.

Before applying: Changing renal function: check creatinine/eGFR at least daily.

Evidence for this qualification

Selected-source comparison; independent clinician adjudication pending.

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Use the fixed-combination table only with its source qualifications

The retrieved dated label has different infusion times by renal category, ambiguous printed MDRD units and an ended marketing entry.

Before applying: Confirm the current exact product and units; retain this as a qualified snapshot, not a cefepime-only substitute.

Also check: Use the fixed-combination table only with its source qualifications

Official source

EXBLIFEP: selected primary-label renal guidance and limits

This source only - not a merged recommendation

What matters first

Product: Adult IV EXBLIFEP for labeled complicated UTI, including pyelonephritis. Not cefepime alone.

Renal action / finding
Use renal band AND infusion duration in the table.
Evidence or dialysis limit
HD timing is explicit; this is not a CRRT regimen. The source is the 2024 FDA label.
Monitoring / application
Changing renal function: check creatinine/eGFR at least daily.

Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.

Product / population
Adult IV EXBLIFEP for labeled complicated UTI, including pyelonephritis. Not cefepime alone.
Renal measure
MDRD eGFR; source table prints mL/min. Indexing is not clarified; do not silently substitute Cockcroft-Gault.
Source revision
02/2024 FDA approval label; not established as latest label
Retrieved
2026-11-07 (not the revision date)
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

HD timing is explicit; this is not a CRRT regimen. The source is the 2024 FDA label.

Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.

Section 2.2/Table 1, PDF pages 3-4

Limits that apply to these rows

Read the complete source-specific limitations above and below this table. No patient dose is calculated.

Source-specific renal instructions
eGFR, source mL/minTotal doseIntervalInfusion
>=1302.5 gEvery 8 hours4 hours
60-1292.5 gEvery 8 hours2 hours
30-591.25 gEvery 8 hours2 hours
15-291.25 gEvery 12 hours2 hours
<15 or intermittent HDDay 1: 1.25 g; then 0.625 gEvery 24 hours2 hours
Read the retained text before reformatting

Table doses are total cefepime/enmetazobactam in a 4:1 ratio. For eGFR <15 or intermittent HD, give 1.25 g on day one, then 0.625 g every 24 hours. Finish HD before dosing. With changing renal function, monitor creatinine/eGFR at least daily. The archived 2024 FDA label was checked; later label currency is not established by this retrieval.

Source revision: 02/2024 FDA approval label; not established as latest label | Retrieved: 2026-11-07. Retrieval date is not the revision date.

Source: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216165s000lbl.pdf

Scope: Selected sections checked against the identified source; not a complete monograph or independent clinician approval. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

EXBLIFEP - cefepime and enmetazobactam injection

Source retrieved 2026-09-10 - confirm current applicability

A regimen is reported in selected content

Read the source and its limits

EXBLIFEP: selected primary-label renal guidance and limits

Source retrieved 2026-11-07 - confirm current applicability

A regimen is reported in selected content

Read the source and its limits

EXBLIFEP: selected RX renal passage

Source retrieved 2026-11-07 - confirm current applicability

A regimen is reported in selected content

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 2 source difference / applicability notes

Official product label

EXBLIFEP - cefepime and enmetazobactam injection

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Dialysis evidence: A regimen is reported in selected content

EXBLIFEP fixed-combination intravenous cefepime/enmetazobactam for its adult indication; not single-agent cefepime. Dated label/currency review remains open.

Renal method: MDRD eGFR; table prints mL/min without indexing denominator
Retrieved: 2026-09-10

Read local renal resultOpen this source quick answerOpen original reference
Official product label

EXBLIFEP: selected primary-label renal guidance and limits

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

HD timing is explicit; this is not a CRRT regimen. The source is the 2024 FDA label.

Dialysis evidence: A regimen is reported in selected content

Adult IV EXBLIFEP for labeled complicated UTI, including pyelonephritis. Not cefepime alone.

Renal method: MDRD eGFR; source table prints mL/min. Indexing is not clarified; do not silently substitute Cockcroft-Gault.
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference
GlobalRPh RX List

EXBLIFEP: selected RX renal passage

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

HD timing is explicit; this is not a CRRT regimen. The source is the 2024 FDA label.

Dialysis evidence: A regimen is reported in selected content

Adult IV EXBLIFEP for labeled complicated UTI, including pyelonephritis. Not cefepime alone.

Renal method: MDRD eGFR; source table prints mL/min. Indexing is not clarified; do not silently substitute Cockcroft-Gault.
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Use the fixed-combination table only with its source qualificationsEXBLIFEP: source applicability and renal evidence limits

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 2 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

combination metric and currency hold

Use the fixed-combination table only with its source qualifications

The retrieved dated label has different infusion times by renal category, ambiguous printed MDRD units and an ended marketing entry.

How to use this: Confirm the current exact product and units; retain this as a qualified snapshot, not a cefepime-only substitute.

EXBLIFEP - cefepime and enmetazobactam injectionCefepime

Source-specific interpretation; independent clinician adjudication pending.

Source scope / renal recommendation differences

EXBLIFEP: source applicability and renal evidence limits

The table names MDRD but prints mL/min without an indexing explanation. Preserve that wording and resolve method/units with the product label and local pharmacy; do not automatically convert the threshold. Archived-label currency remains a hold.

How to use this: Changing renal function: check creatinine/eGFR at least daily.

EXBLIFEP: selected primary-label renal guidance and limitsEXBLIFEP: selected RX renal passage

Selected-source comparison; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Official source

EXBLIFEP: selected primary-label renal guidance and limits

Adult IV EXBLIFEP for labeled complicated UTI, including pyelonephritis. Not cefepime alone.

Method: MDRD eGFR; source table prints mL/min. Indexing is not clarified; do not silently substitute Cockcroft-Gault.

Read this complete source summary
Rxlist source

EXBLIFEP: selected RX renal passage

Adult IV EXBLIFEP for labeled complicated UTI, including pyelonephritis. Not cefepime alone.

Method: MDRD eGFR; source table prints mL/min. Indexing is not clarified; do not silently substitute Cockcroft-Gault.

Read this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeEXBLIFEP - cefepime and enmetazobactam injectionEXBLIFEP: selected primary-label renal guidance and limitsEXBLIFEP: selected RX renal passage
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2da031b1-07ff-48f3-88d2-7e86ba93048a

Exact product and population

EXBLIFEP fixed-combination intravenous cefepime/enmetazobactam for its adult indication; not single-agent cefepime. Dated label/currency review remains open.

RDM58-SCOPE-cefepime-enmetazobactam-exblifep · Source section: Selected source product scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

EXBLIFEP - cefepime and enmetazobactam injection

Open original reference

Open / share this exact local source

DailyMed / Allecra Therapeutics SAS · EXBLIFEP fixed-combination intravenous cefepime/enmetazobactam for its adult indication; not single-agent cefepime. Dated label/currency review remains open.

Renal method: MDRD eGFR; table prints mL/min without indexing denominator
Source date: 2/2024
Retrieved: 2026-09-10

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Dialysis evidence: A regimen is reported in selected content

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The dated label names MDRD eGFR but prints mL/min without an indexing denominator. Its adult table gives combined doses: 60-129, 2.5 g every 8 hours over 2 hours; >=130, the same dose/interval over 4 hours; 30-59, 1.25 g every 8 hours; 15-29, 1.25 g every 12 hours; below 15 or intermittent HD, first-day 1.25 g loading dose then 0.625 g every 24 hours. All reduced regimens infuse over 2 hours; give after HD.

For changing renal function, check serum creatinine/eGFR at least daily. Neurotoxicity can occur despite appropriate adjustment. The retrieved 2024 label has an ended marketing entry: confirm the current product and renal-measure convention, and do not substitute a cefepime-only table.

RDM58-official-cefepime-enmetazobactam-exblifep-8be928f85a-C1 · Source locator: Sections 2.2 (Table 1), 5.2; document-end metadata and marketing information

Source-specific limits

Selected sections only; not a complete prescribing monograph or independent clinician approval.

Exact DailyMed HTML identity and named sections read. Raw SPL XML, original document hash and complete revision history were not obtained. Availability is not established by label retrieval.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2da031b1-07ff-48f3-88d2-7e86ba93048a
Retrieved
2026-09-10
Exact label title
EXBLIFEP - cefepime and enmetazobactam injection
DailyMed Set ID
2da031b1-07ff-48f3-88d2-7e86ba93048a
Labeler
Allecra Therapeutics SAS
Label revision
2/2024
SPL version
3
FDA application
NDA216165
Renal-function method
MDRD eGFR; table prints mL/min without indexing denominator
Source date/version
2/2024
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
a1c19e2e99e80e2e73cd34d9f13f39245bd2f4dac0ca6cc7fc71ca1c1661dabd
Official

EXBLIFEP: selected primary-label renal guidance and limits

Open original reference

Open / share this exact local source

FDA / archived approval prescribing information · Adult IV EXBLIFEP for labeled complicated UTI, including pyelonephritis. Not cefepime alone.

Renal method: MDRD eGFR; source table prints mL/min. Indexing is not clarified; do not silently substitute Cockcroft-Gault.
Source date: 02/2024 FDA approval label; not established as latest label
Retrieved: 2026-11-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

HD timing is explicit; this is not a CRRT regimen. The source is the 2024 FDA label.

Dialysis evidence: A regimen is reported in selected content

Selected sections checked against the identified source; not a complete monograph or independent clinician approval.

Section 2.2/Table 1, PDF pages 3-4

Limits that apply to these rows

Read the complete source-specific limitations above and below this table. No patient dose is calculated.

Source-specific renal instructions
eGFR, source mL/minTotal doseIntervalInfusion
>=1302.5 gEvery 8 hours4 hours
60-1292.5 gEvery 8 hours2 hours
30-591.25 gEvery 8 hours2 hours
15-291.25 gEvery 12 hours2 hours
<15 or intermittent HDDay 1: 1.25 g; then 0.625 gEvery 24 hours2 hours
Read the retained text before reformatting

Table doses are total cefepime/enmetazobactam in a 4:1 ratio. For eGFR <15 or intermittent HD, give 1.25 g on day one, then 0.625 g every 24 hours. Finish HD before dosing. With changing renal function, monitor creatinine/eGFR at least daily. The archived 2024 FDA label was checked; later label currency is not established by this retrieval.

RDM72-cefepime-enmetazobactam-exblifep-label-1 · Source locator: Section 2.2/Table 1, PDF pages 3-4

Source-specific limits

Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.

Source identity and provenance
Source family
product_label
Source
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216165s000lbl.pdf
Retrieved
2026-11-07
Renal-function method
MDRD eGFR; source table prints mL/min. Indexing is not clarified; do not silently substitute Cockcroft-Gault.
Source date/version
02/2024 FDA approval label; not established as latest label
Hash meaning
Locally authored summary text; not original source HTML, XML or PDF bytes
Local summary SHA-256
c8385bb837e14ce5256a4a1883df51565709cf9f1e9f13ef538404cab58e1b1d
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

EXBLIFEP: selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / label mirror · Adult IV EXBLIFEP for labeled complicated UTI, including pyelonephritis. Not cefepime alone.

Renal method: MDRD eGFR; source table prints mL/min. Indexing is not clarified; do not silently substitute Cockcroft-Gault.
Source date: Revision date not established in reviewed mirror passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

HD timing is explicit; this is not a CRRT regimen. The source is the 2024 FDA label.

Dialysis evidence: A regimen is reported in selected content

Selected sections checked against the identified source; not a complete monograph or independent clinician approval.

Section 2.2/Table 1, PDF pages 3-4

The mirror includes the MDRD-based renal table, a four-hour infusion at eGFR >=130, lower maintenance doses in impairment, and post-HD administration. The method and units must be checked rather than relabeled as CrCl.

RDM72-cefepime-enmetazobactam-exblifep-rx-1 · Source locator: Section 2.2/Table 1, PDF pages 3-4

Source-specific limits

Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/exblifep-drug/
Retrieved
2026-11-07
Renal-function method
MDRD eGFR; source table prints mL/min. Indexing is not clarified; do not silently substitute Cockcroft-Gault.
Source date/version
Revision date not established in reviewed mirror passage.
Hash meaning
Locally authored summary text; not original source HTML, XML or PDF bytes
Local summary SHA-256
f860820e45c94e2f694c150604ef73dd6436e018bbeaf034a1282da58622f67d

Provenance and preservation

Additional summaries stored on this page: 2 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2da031b1-07ff-48f3-88d2-7e86ba93048a
Source retrieval
2026-09-10. This is not the source publication or label revision date.
Original source type
source summary
Local text SHA-256
b80ecd1ce047b70a7c557884d8166f6d62ba7f690cbb952c5a1fb58e46f0b727
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report
Top